Breaking News on Contract Research, Manufacturing & Clinical Trials

Headlines > Preclinical Research

Dynal launches new tool for immunotherapy

By Wai Lang Chu , 06-Jul-2006

Dynal has announced today the release of a new research tool in its immunotherapy range that allow researchers to isolate and collect T cells from immunocompromised patients for ex vivo stimulation and expansion in a sterile environment.

The function has played a major part in certain clinical applications, which include autoimmune diseases as well as gene and stem cell applications. Boosted T cells, if reinfused, have the potential to strengthen the individual's immune system to fight diseases, for example cancer and HIV.

The Dynabeads ClinExVivo CD3/CD28 superparamagnetic beads are designed with an optimised surface covered with primary CD3 and co-stimulatory CD28 antibodies.

Following a short ex vivo incubation with the patient's sample, the beads bind with the T cells. The beads and bound T cells are separated from the rest of the sample using the special Dynal ClinExVivo

MPC magnet. Researchers then stimulate and expand the T cells ex vivo with Dynabeads ClinExVivo CD3/CD28 in a sterile environment prior to reintroduction to the patient.

"Already this innovative technology has been used for several phase I/II trials in cancer patients," said Dynal's international product manager, Erik Ruud.

"Data from studies using ex vivo manipulated T cells in cancer and vaccine therapy were recently presented at the International Society for Cell Therapy (ISCT) conference during a special symposium on "T Cell-based Immunotherapeutic Strategies."

Dynabeads are superparamagnetic, which exhibit magnetic properties only when placed within a magnetic field and show no residual magnetism when removed from this field.

In the US, Dynabeads ClinExVivo CD3/CD28 are available for clinical applications only under an approved IND application.

Subscribe to our FREE newsletter

Get FREE access to authoritative breaking news, videos, podcasts, webinars and white papers. SUBSCRIBE